Plasma lipid profile in pregnant women with HIV receiving nevirapine

Marco Floridia, Enrica Tamburrini, Gianfranco Anzidei, Cecilia Tibaldi, Giovanni Guaraldi, Brunella Guerra, Alessandra Meloni, Antonella Vimercati, Atim Molinari, Carmela Pinnetti, Serena Dalzero, Marina Ravizza

Research output: Contribution to journalArticlepeer-review


Limited information is currently available on the metabolic profile of nevirapine in pregnancy. We used data from a national observational study to evaluate plasma lipid profile in pregnant women receiving nevirapine. Lipid values were collected during routine clinical visits. Midpregnancy (second trimester) lipid values were analyzed according to use of nevirapine, calculating differences and 95% confidence intervals (CI) between women taking and not taking this drug. In order to adjust for possible confounders, multivariable models were constructed using as dependent variables levels of total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglyceride (TG) levels and TC/HDL-C ratio, and as independent variables age, body weight, previous treatment history, CD4 count, and presence of any antiretroviral therapy, use or nonuse of protease inhibitors, stavudine, and nevirapine at the time of blood sampling. Overall, 375 women had available data for analysis. Pregnant women on nevirapine, compared to women not taking this drug, had in univariate analyses higher levels of HDL-C (difference: +13.0mg/dL [95%CI 7.4-18.6], p

Original languageEnglish
Pages (from-to)147-152
Number of pages6
JournalAIDS Patient Care and STDs
Issue number3
Publication statusPublished - Mar 1 2009

ASJC Scopus subject areas

  • Infectious Diseases
  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Plasma lipid profile in pregnant women with HIV receiving nevirapine'. Together they form a unique fingerprint.

Cite this